All News
Problem w antibodies to prevent #COVID19 infection in rheumatic Pts is that they are not as good in variants that are more prominent ex Omicron strains. But should we use in high risk Pts ex long rituximab users? I do in this group. @RheumNow #ACR22 https://t.co/A8soYbg9ZD
Janet Pope Janetbirdope ( View Tweet)
Baraliakos et al. AEs with SC vs IV infliximab. Relatively comparable safety profiles. Higher administration site reactions in SC. @RheumNow #ACR22 Abstr#1769 https://t.co/KnYlvifDlr https://t.co/VnKOYs86Xz
Richard Conway RichardPAConway ( View Tweet)
Does tofacitinib work better in patients with PsA and AS who smoke?
Abstract #1036 #ACR22 @RheumNow
🚬519 ever smokers
🚭767 never smokers
💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO
✋Overall, efficacy was generally comparable in ever v. never 🚬
Catherine Sims, MD DrCassySims ( View Tweet)
Lillegraven @SiriLillegraven ARCTIC REWIND. RA patients flare-free on half-dose csDMARD x 12 months - randomised to continue or stop. Flare 38% vs 17% over 12 months. DAS remission 96% vs 90%. Absence radiograph prog 84% vs 69% @RheumNow #ACR22 Abstr#2013 https://t.co/uOwd8Io5wZ https://t.co/SKWPE7GBrx
Richard Conway RichardPAConway ( View Tweet)
⚡️PNEUMOVAS⚡️
💉reinforced anti pneumococcal vaccine in AAV pts on Rituximab💉
👉Reinforced regimen (double dose PCV13 D0/D7 wt PPV23 @ M5) - sig ⬆️ Ab response 2 strep pneum
❓application 2
👉other vaccines
👉 other RTX tx IMRD
#ACR22 AbstL16 @RheumNow @TerrierBen https://t.co/BnZWAoHDj6
Patricia Harkins DrTrishHarkins ( View Tweet)
Maksymowych et al. RCT ofAdalimumab for knee OA!? it doesn't work. @RheumNow #ACR22 Abstr#1891 https://t.co/pfPVJ9A1Ex https://t.co/X7sLEaqGvT
Richard Conway RichardPAConway ( View Tweet)
@RheumNow video live from #ACR22
Ab0675: Diffuse alveolar hemorrhage in APLS
https://t.co/8BDyxzAGJ2
Eric Dein ericdeinmd ( View Tweet)
What’s new w #classification for #APS? You don’t have to have 2 positive tests disseminated in time. BUT remember the the labs for anticardiolipin are shockingly variable btwn centres. @RheumNow #ACR22 https://t.co/NTqQ6h7fws
Janet Pope Janetbirdope ( View Tweet)
Abstract #PP25
Patient mantra on life with SpA: “not to over-exert the body on your good days and always strive to be active on your bad days”
Patient recommended exercise:
🏓table tennis
🏊♂️swimming
🧘yoga
🤸tai chi
#ACR22 @RheumNow
Catherine Sims, MD DrCassySims ( View Tweet)
Staggering stats after a #osteoporosis hip fracture!
40% cannot walk independently
30% have a permanent disability
20% mortality in surgically fixed hip
40% mortality if not surgically fixed. -Dr. M Humphrey #ACR22 @rheumnow https://t.co/DSYQjDw6pW
TheDaoIndex KDAO2011 ( View Tweet)
Dose Matters!
Steroid doses as little as 2.5 mg/day when taken chronically increase risk for fractures #ACR22 @rheumnow https://t.co/fIocJtebkI
TheDaoIndex KDAO2011 ( View Tweet)
Morales et al. AUR200, novel BAFF/APRIL inhibitor. Looking promising in pre-clinical and animal models. We will wait and see! @RheumNow #ACR22 Abstr#1629 https://t.co/htmX2GHV3X https://t.co/jvhFdx2c52
Richard Conway RichardPAConway ( View Tweet)
MOA of how steroids cause #osteoporosis #ACR22 @rheumnow https://t.co/k6MvftH4AV
TheDaoIndex KDAO2011 ( View Tweet)
Lin et al. Genetic risk (HR 2.3 women, 2.63 men) and lifestyle (HR 5.7 for women, 3.7 for men) both individual contributors and synergistic (HR 9.1 women, 8.7 men) in gout development in both men and women. Modifiable! @RheumNow #ACR22 Abstr#1633 https://t.co/51KPgfXn1w https://t.co/gOU7DfOKvt
Richard Conway RichardPAConway ( View Tweet)
PMR is no a disease of vague shoulder and hip pain.
It's something much more specific:
a chronic inflammatory disease of musculotendinous structures.
We're starting to understand the real story.
@drceowen lays it out for #ACR22 this morning
@EBRheum @SattuiSEMD @RheumNow https://t.co/thqtCwSULM
David Liew drdavidliew ( View Tweet)
Bimekizumab (BKZ) in AxSpA to Wk52
◦ sustained efficacy
◦ suppression of inflammation
◦ improvements in function and quality of life
◦ no new safety signals were observed
◦ consistent with the safety profileWk24 data
Baraliakos #L14 https://t.co/gk23g4vqQl #ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Fernandes et al. CPPD assoc increased nephrolithiasis. 8.06% vs 4.88%; p<0.0001. @RheumNow #ACR22 Abstr#1819 https://t.co/o8Afmcc429 https://t.co/3EoOXpqpGN
Richard Conway RichardPAConway ( View Tweet)
Chen et al. Appendicitis associated increased risk incident SLE in population-based case-control study from Taiwan. HR 2.04 @RheumNow #ACR22 Abstr#1750 https://t.co/L9dTpMdHNP https://t.co/mEHeL6JnuE
Richard Conway RichardPAConway ( View Tweet)
Parperis et al. Cypriot population based study. ACS in CPPD assoc longer LOS, and increased mortality 6.9% vs 5.6% (p<0.001). @RheumNow #ACR22 Abstr#1817 https://t.co/uWv67aZa9L https://t.co/3oRFXREcYx
Richard Conway RichardPAConway ( View Tweet)
Helget et al. Subanalysis of STOP Gout. Allopurinol and febuxostat equal efficacy in CKD 3. More AKI with allopurinol 8.3% vs 2.4%. @RheumNow #ACR22 Abstr#1829 https://t.co/Z4JqYp4mTT https://t.co/xd8VGJVkNo
Richard Conway RichardPAConway ( View Tweet)